TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS

医学肿瘤学部、药学院和骨髓移植计划将在“抗肿瘤药物的临床药理学”中发起一个跨学科的博士后培训计划。该培训计划的目标是为个人提供开发抗肿瘤药物所需的复杂技能，评估其性能，设计临床研究，并通过监管机构将这些药物纳入国家试验。参与此次培训的导师认为，受过化疗药物实际评估培训的科学家有重要需求，以促进这些药物从实验室工作台到床边的移动。医学肿瘤学部、药学院和骨髓移植计划拥有特殊的研究和临床资源，可以培训博士后研究员，掌握抗肿瘤药物的临床前评估、临床试验设计和药理学科学评估所需的完整技能。这一培训计划将向完成一年临床培训的临床肿瘤学研究员和完成与该计划相关领域的博士培训的博士生开放。该计划将包括2-3年的基础实验室研究培训，必修的核心课程，可供选择的系列讲座和选修课。它将由一个由三个合作单位的主任组成的执行委员会管理，学生的进步将由一个由三名教员组成的导师委员会监督。受训者将被要求提交NIH风格的R0-1，本地研究研讨会，参加全国会议，并在同行评议的期刊上发表文章。项目总监将对学员进行为期6个月的评估。这一独特的培训计划提供了一个互动的环境，参与抗肿瘤药物开发的所有阶段的医学博士和博士将对个人进行必要的临床前和临床科学培训，将抗癌药物从试验台带到床边。

The Division of Medical Oncology, School of Pharmacy, and the Bone Marrow Transplant Program will sponsor an interdisciplinary postdoctoral training program in the "Clinical Pharmacology of Antineoplastic Agents." The goal of this training program is to provide individuals with the complex skills necessary to develop antineoplastic agents,e valuate their properties, design clinical studies, and move these agents through the regulatory agencies into national trials. The preceptors involved in this training believe that there is an important need for scientists who are trained in the practical evaluation of chemotherapeutic agents to facilitate the movement of these agents from the laboratory bench to the bedside. The Division of Medical Oncology, School of Pharmacy, and the Bone Marrow Transplant Program have exceptional research and clinical resources to train postdoctoral fellows in the complete range of skills which are necessary for the preclinical evaluation of antineoplastic agents, the design of clinical trials, and the scientific evaluation of the pharmacology. This training program will be open to Clinical Oncology Fellows who have completed one year of clinical training, and to Ph.D.s who have completed doctoral training in areas relevant to this program. The program will include 2-3 years of basic laboratory research training, required core courses, available lecture series, and elective courses. It will be administered by an Executive committee consisting of the directors of the three cooperating units, and student progress will be monitored by a Mentor's Committee of three faculty members. Trainees will be required to present an NIH style R0-1, local research seminars, attend national meetings, and publish articles in peer-reviewed journals. The trainee will be evaluated on a 6 month basis by the Program Director. This unique training program provides an interactive environment in which MDs and Ph.D.s involved in all phases of antineoplastic agent development will train individuals in the preclinical and clinical science necessary to take anti-cancer agents from the bench to the bedside.